Diabetes drug Mounjaro could prevent heart attacks and strokes finds major trial

A major medical breakthrough for people living with type 2 diabetes has been revealed, with a global trial suggesting the drug Mounjaro could prevent heart attacks and strokes.

The world’s biggest and longest trial of Mounjaro has delivered surprising results, showing the drug doesn’t just slim waistlines and lower blood sugar levels, but also saves lives.

“These are really important safety findings and cardiometabolic outcomes for people with type 2 diabetes,” researchers said.

In the five-year study of more than 13,000 patients across 30 countries, researchers found Mounjaro reduced deaths from all causes, including heart attack and stroke, while also protecting against some kidney failure.

“It’s possible weight loss could explain much of the benefit, but further study is needed,” the study noted.

Medical professionals are expressing confidence in the drug’s long-term safety profile.

“There were no new safety concerns in this clinical trial, so that gives me as a clinician confidence in using this as a long-term medication for my patients,” one doctor said.

Ron, who took part in the trial, says the difference has been life-changing.

“I’ve lost about 35 kilos. I feel fantastic,” he said.

However, while the results look promising, the trial was run and funded by the company itself that’s lobbying hard for government subsidies.

Three times, the Pharmaceutical Benefits Advisory Committee has delayed listing Mounjaro on the PBS. Another decision is due in November, but 7NEWS can reveal that the committee is concerned the company is inflating the price and that subsidising the drug could lead to widespread misuse.

Despite these concerns, doctors say approval is necessary.

“Absolutely, it should be listed on the PBS, and we’re optimistic that it will get approval,” medical experts said.